10x Genomics (NASDAQ:TXG) Stock Has Average Price Target of $68.00

Shares of 10x Genomics (NASDAQ:TXG) have received an average rating of “Hold” from the eighteen ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, twelve have given a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $68.07.

Several brokerages have recently issued reports on TXG. Weiss Ratings restated a “sell (d-)” rating on shares of 10x Genomics in a report on Monday, September 21st. Morgan Stanley lifted their price target on shares of 10x Genomics from $40.00 to $70.00 and gave the stock an “equal weight” rating in a research note on Monday, October 12th. Stifel Nicolaus boosted their price target on shares of 10x Genomics from $50.00 to $68.00 and gave the company a “buy” rating in a research report on Friday. UBS Group reduced their price target on shares of 10x Genomics from $90.00 to $61.00 and set a “neutral” rating for the company in a research report on Friday. Finally, Argus began coverage on shares of 10x Genomics in a research note on Monday, September 28th. They issued a “buy” rating and a $110.00 price objective for the company.

Insider Buying and Selling at 10x Genomics

In related news, CFO Adam Taich sold 46,388 shares of the company’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $64.57, for a total value of $2,995,273.16. Following the completion of the sale, the chief financial officer directly owned 316,344 shares of the company’s stock, valued at $20,426,332.08. This represents a 12.79% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John R. Stuelpnagel sold 20,000 shares of the company’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $61.75, for a total value of $1,235,000.00. Following the completion of the sale, the director directly owned 328,436 shares of the company’s stock, valued at approximately $20,280,923. This trade represents a 5.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 179,333 shares of company stock valued at $11,810,070. 8.84% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Sei Investments Co. increased its holdings in shares of 10x Genomics by 113.5% in the 1st quarter. Sei Investments Co. now owns 44,679 shares of the company’s stock valued at $949,000 after acquiring an additional 23,748 shares during the period. Squarepoint Ops LLC purchased a new stake in 10x Genomics in the 2nd quarter valued at $2,069,000. HB Wealth Management LLC purchased a new stake in 10x Genomics in the 2nd quarter valued at $285,000. Proficio Capital Partners LLC acquired a new stake in 10x Genomics during the 2nd quarter worth $781,000. Finally, Hsbc Holdings PLC acquired a new stake in 10x Genomics during the 1st quarter worth $5,945,000. Institutional investors and hedge funds own 84.68% of the company’s stock.

Key Stories Impacting 10x Genomics

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: 10x Genomics reported a Q3 loss of $0.15 per share, narrower than analysts’ expectations, while revenue of $150.7 million topped estimates. The company also raised its 2026 revenue outlook to $625 million–$635 million, above the roughly $620 million consensus. Q3 results
• Positive Sentiment: The company launched Sentira Single Cell, an AI-powered tool intended to simplify cell-data analysis. The product could support research adoption and create recurring revenue opportunities. Sentira launch
• Neutral Sentiment: Citigroup raised its price target from $50 to $60 but kept a neutral rating, suggesting limited upside at the cited share price. Citi target update
• Negative Sentiment: UBS cut its target from $90 to $61 and maintained a neutral rating. Meanwhile, Q3 revenue grew just 1.1% year over year and the company remains loss-making; management also cited production constraints and margin pressure, tempering optimism around stronger Atera demand. UBS target update Q3 call highlights

10x Genomics Price Performance

TXG stock opened at $59.28 on Friday. The business has a 50 day moving average price of $73.95 and a 200 day moving average price of $41.59. The stock has a market cap of $7.72 billion, a price-to-earnings ratio of -114.00 and a beta of 2.03. 10x Genomics has a fifty-two week low of $13.58 and a fifty-two week high of $102.81.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.12. 10x Genomics had a negative net margin of 10.84% and a negative return on equity of 8.26%. The company had revenue of $150.67 million for the quarter, compared to analyst estimates of $147.96 million. During the same period in the prior year, the firm posted ($0.22) earnings per share. The firm’s revenue was up 1.1% on a year-over-year basis. As a group, sell-side analysts anticipate that 10x Genomics will post -0.77 EPS for the current year.

10x Genomics Company Profile

10x Genomics, Inc develops technology for studying biological systems at single-cell and spatial resolution. Its instruments, consumables and software help researchers analyze gene expression and other features of cells while preserving information about their location within tissue.

The company’s product platforms include Chromium for single-cell analysis, Visium for spatial gene-expression analysis and Xenium for in situ analysis of gene activity within tissue samples. Its tools are used in areas such as immunology, neuroscience, cancer research and drug discovery.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves research and clinical customers around the world, including academic institutions, biotechnology and pharmaceutical companies, and other research organizations.